Serveur d'exploration COVID et hydrochloroquine

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Thyroid disorders and SARS-CoV-2 infection: From pathophysiological mechanism to patient management.

Identifieur interne : 000A75 ( Main/Exploration ); précédent : 000A74; suivant : 000A76

Thyroid disorders and SARS-CoV-2 infection: From pathophysiological mechanism to patient management.

Auteurs : Philippe Caron [France]

Source :

RBID : pubmed:32950466

Descripteurs français

English descriptors

Abstract

The World Health Organization (WHO) declared the COVID-19 epidemic to be a global pandemic in March 2020. COVID-19 is an infection caused by SARS-CoV-2, a coronavirus that utilizes the angiotensin-2 converting enzyme to penetrate thyroid and pituitary cells, and may result in a "cytokine storm". Based on the pathophysiological involvement of the pituitary-thyroid axis, the current review discusses the diagnosis of abnormal thyroid function test, and the management of patients presenting with thyrotoxicosis, thyroid-associated orbitopathy and hypothyroidism in the context of SARS-CoV-2 infection.

DOI: 10.1016/j.ando.2020.09.001
PubMed: 32950466
PubMed Central: PMC7498405


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Thyroid disorders and SARS-CoV-2 infection: From pathophysiological mechanism to patient management.</title>
<author>
<name sortKey="Caron, Philippe" sort="Caron, Philippe" uniqKey="Caron P" first="Philippe" last="Caron">Philippe Caron</name>
<affiliation wicri:level="3">
<nlm:affiliation>Service d'endocrinologie et maladies métaboliques, pôle cardiovasculaire et métabolique, CHU Larrey, 24, chemin de Pouvourville, TSA 30030, 31059 Toulouse cedex, France. Electronic address: caron.p@chu-toulouse.fr.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Service d'endocrinologie et maladies métaboliques, pôle cardiovasculaire et métabolique, CHU Larrey, 24, chemin de Pouvourville, TSA 30030, 31059 Toulouse cedex</wicri:regionArea>
<placeName>
<region type="region" nuts="2">Occitanie (région administrative)</region>
<region type="old region" nuts="2">Midi-Pyrénées</region>
<settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32950466</idno>
<idno type="pmid">32950466</idno>
<idno type="doi">10.1016/j.ando.2020.09.001</idno>
<idno type="pmc">PMC7498405</idno>
<idno type="wicri:Area/Main/Corpus">000B91</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000B91</idno>
<idno type="wicri:Area/Main/Curation">000B91</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000B91</idno>
<idno type="wicri:Area/Main/Exploration">000B91</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Thyroid disorders and SARS-CoV-2 infection: From pathophysiological mechanism to patient management.</title>
<author>
<name sortKey="Caron, Philippe" sort="Caron, Philippe" uniqKey="Caron P" first="Philippe" last="Caron">Philippe Caron</name>
<affiliation wicri:level="3">
<nlm:affiliation>Service d'endocrinologie et maladies métaboliques, pôle cardiovasculaire et métabolique, CHU Larrey, 24, chemin de Pouvourville, TSA 30030, 31059 Toulouse cedex, France. Electronic address: caron.p@chu-toulouse.fr.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Service d'endocrinologie et maladies métaboliques, pôle cardiovasculaire et métabolique, CHU Larrey, 24, chemin de Pouvourville, TSA 30030, 31059 Toulouse cedex</wicri:regionArea>
<placeName>
<region type="region" nuts="2">Occitanie (région administrative)</region>
<region type="old region" nuts="2">Midi-Pyrénées</region>
<settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<series>
<title level="j">Annales d'endocrinologie</title>
<idno type="eISSN">2213-3941</idno>
<imprint>
<date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Angiotensin-Converting Enzyme 2 (MeSH)</term>
<term>Apoptosis (MeSH)</term>
<term>Betacoronavirus (MeSH)</term>
<term>COVID-19 (MeSH)</term>
<term>Coronavirus Infections (complications)</term>
<term>Coronavirus Infections (drug therapy)</term>
<term>Coronavirus Infections (physiopathology)</term>
<term>Cytokine Release Syndrome (etiology)</term>
<term>Cytokine Release Syndrome (physiopathology)</term>
<term>Disease Susceptibility (MeSH)</term>
<term>Graves Ophthalmopathy (complications)</term>
<term>Humans (MeSH)</term>
<term>Hydroxychloroquine (adverse effects)</term>
<term>Hydroxychloroquine (therapeutic use)</term>
<term>Hypothyroidism (blood)</term>
<term>Hypothyroidism (etiology)</term>
<term>Hypothyroidism (physiopathology)</term>
<term>Interleukin-6 (physiology)</term>
<term>Pandemics (MeSH)</term>
<term>Peptidyl-Dipeptidase A (analysis)</term>
<term>Pituitary Gland (physiopathology)</term>
<term>Pneumonia, Viral (complications)</term>
<term>Pneumonia, Viral (drug therapy)</term>
<term>Pneumonia, Viral (physiopathology)</term>
<term>Receptors, Virus (analysis)</term>
<term>SARS-CoV-2 (MeSH)</term>
<term>Thyroid Diseases (blood)</term>
<term>Thyroid Diseases (etiology)</term>
<term>Thyroid Diseases (physiopathology)</term>
<term>Thyroid Gland (chemistry)</term>
<term>Thyroid Gland (pathology)</term>
<term>Thyroid Gland (physiopathology)</term>
<term>Thyroid Hormones (blood)</term>
<term>Thyrotoxicosis (blood)</term>
<term>Thyrotoxicosis (etiology)</term>
<term>Thyrotoxicosis (physiopathology)</term>
<term>Thyrotropin (blood)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>Apoptose (MeSH)</term>
<term>Betacoronavirus (MeSH)</term>
<term>Glande thyroide (anatomopathologie)</term>
<term>Glande thyroide (composition chimique)</term>
<term>Glande thyroide (physiopathologie)</term>
<term>Hormones thyroïdiennes (sang)</term>
<term>Humains (MeSH)</term>
<term>Hydroxychloroquine (effets indésirables)</term>
<term>Hydroxychloroquine (usage thérapeutique)</term>
<term>Hypophyse (physiopathologie)</term>
<term>Hypothyroïdie (physiopathologie)</term>
<term>Hypothyroïdie (sang)</term>
<term>Hypothyroïdie (étiologie)</term>
<term>Infections à coronavirus (complications)</term>
<term>Infections à coronavirus (physiopathologie)</term>
<term>Infections à coronavirus (traitement médicamenteux)</term>
<term>Interleukine-6 (physiologie)</term>
<term>Maladies de la thyroïde (physiopathologie)</term>
<term>Maladies de la thyroïde (sang)</term>
<term>Maladies de la thyroïde (étiologie)</term>
<term>Ophtalmopathie basedowienne (complications)</term>
<term>Pandémies (MeSH)</term>
<term>Peptidyl-Dipeptidase A (analyse)</term>
<term>Pneumopathie virale (complications)</term>
<term>Pneumopathie virale (physiopathologie)</term>
<term>Pneumopathie virale (traitement médicamenteux)</term>
<term>Prédisposition aux maladies (MeSH)</term>
<term>Récepteurs viraux (analyse)</term>
<term>Thyréostimuline (sang)</term>
<term>Thyréotoxicose (physiopathologie)</term>
<term>Thyréotoxicose (sang)</term>
<term>Thyréotoxicose (étiologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en">
<term>Hydroxychloroquine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en">
<term>Peptidyl-Dipeptidase A</term>
<term>Receptors, Virus</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en">
<term>Thyroid Hormones</term>
<term>Thyrotropin</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="physiology" xml:lang="en">
<term>Interleukin-6</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en">
<term>Hydroxychloroquine</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en">
<term>Angiotensin-Converting Enzyme 2</term>
</keywords>
<keywords scheme="MESH" qualifier="analyse" xml:lang="fr">
<term>Peptidyl-Dipeptidase A</term>
<term>Récepteurs viraux</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr">
<term>Glande thyroide</term>
</keywords>
<keywords scheme="MESH" qualifier="blood" xml:lang="en">
<term>Hypothyroidism</term>
<term>Thyroid Diseases</term>
<term>Thyrotoxicosis</term>
</keywords>
<keywords scheme="MESH" qualifier="chemistry" xml:lang="en">
<term>Thyroid Gland</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en">
<term>Coronavirus Infections</term>
<term>Graves Ophthalmopathy</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="composition chimique" xml:lang="fr">
<term>Glande thyroide</term>
<term>Infections à coronavirus</term>
<term>Ophtalmopathie basedowienne</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en">
<term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr">
<term>Hydroxychloroquine</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en">
<term>Cytokine Release Syndrome</term>
<term>Hypothyroidism</term>
<term>Thyroid Diseases</term>
<term>Thyrotoxicosis</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en">
<term>Thyroid Gland</term>
</keywords>
<keywords scheme="MESH" qualifier="physiologie" xml:lang="fr">
<term>Interleukine-6</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathologie" xml:lang="fr">
<term>Glande thyroide</term>
<term>Hypophyse</term>
<term>Hypothyroïdie</term>
<term>Infections à coronavirus</term>
<term>Maladies de la thyroïde</term>
<term>Pneumopathie virale</term>
<term>Thyréotoxicose</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en">
<term>Coronavirus Infections</term>
<term>Cytokine Release Syndrome</term>
<term>Hypothyroidism</term>
<term>Pituitary Gland</term>
<term>Pneumonia, Viral</term>
<term>Thyroid Diseases</term>
<term>Thyroid Gland</term>
<term>Thyrotoxicosis</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr">
<term>Hormones thyroïdiennes</term>
<term>Hypothyroïdie</term>
<term>Maladies de la thyroïde</term>
<term>Thyréostimuline</term>
<term>Thyréotoxicose</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr">
<term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr">
<term>Hydroxychloroquine</term>
</keywords>
<keywords scheme="MESH" qualifier="étiologie" xml:lang="fr">
<term>Hypothyroïdie</term>
<term>Maladies de la thyroïde</term>
<term>Thyréotoxicose</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Apoptosis</term>
<term>Betacoronavirus</term>
<term>COVID-19</term>
<term>Disease Susceptibility</term>
<term>Humans</term>
<term>Pandemics</term>
<term>SARS-CoV-2</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr">
<term>Apoptose</term>
<term>Betacoronavirus</term>
<term>Humains</term>
<term>Pandémies</term>
<term>Prédisposition aux maladies</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">The World Health Organization (WHO) declared the COVID-19 epidemic to be a global pandemic in March 2020. COVID-19 is an infection caused by SARS-CoV-2, a coronavirus that utilizes the angiotensin-2 converting enzyme to penetrate thyroid and pituitary cells, and may result in a "cytokine storm". Based on the pathophysiological involvement of the pituitary-thyroid axis, the current review discusses the diagnosis of abnormal thyroid function test, and the management of patients presenting with thyrotoxicosis, thyroid-associated orbitopathy and hypothyroidism in the context of SARS-CoV-2 infection.</div>
</front>
</TEI>
<pubmed>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">32950466</PMID>
<DateCompleted>
<Year>2020</Year>
<Month>10</Month>
<Day>29</Day>
</DateCompleted>
<DateRevised>
<Year>2020</Year>
<Month>12</Month>
<Day>10</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">2213-3941</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>81</Volume>
<Issue>5</Issue>
<PubDate>
<Year>2020</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Annales d'endocrinologie</Title>
<ISOAbbreviation>Ann Endocrinol (Paris)</ISOAbbreviation>
</Journal>
<ArticleTitle>Thyroid disorders and SARS-CoV-2 infection: From pathophysiological mechanism to patient management.</ArticleTitle>
<Pagination>
<MedlinePgn>507-510</MedlinePgn>
</Pagination>
<ELocationID EIdType="pii" ValidYN="Y">S0003-4266(20)31214-2</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ando.2020.09.001</ELocationID>
<Abstract>
<AbstractText>The World Health Organization (WHO) declared the COVID-19 epidemic to be a global pandemic in March 2020. COVID-19 is an infection caused by SARS-CoV-2, a coronavirus that utilizes the angiotensin-2 converting enzyme to penetrate thyroid and pituitary cells, and may result in a "cytokine storm". Based on the pathophysiological involvement of the pituitary-thyroid axis, the current review discusses the diagnosis of abnormal thyroid function test, and the management of patients presenting with thyrotoxicosis, thyroid-associated orbitopathy and hypothyroidism in the context of SARS-CoV-2 infection.</AbstractText>
<CopyrightInformation>Copyright © 2020 Elsevier Masson SAS. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Caron</LastName>
<ForeName>Philippe</ForeName>
<Initials>P</Initials>
<AffiliationInfo>
<Affiliation>Service d'endocrinologie et maladies métaboliques, pôle cardiovasculaire et métabolique, CHU Larrey, 24, chemin de Pouvourville, TSA 30030, 31059 Toulouse cedex, France. Electronic address: caron.p@chu-toulouse.fr.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2020</Year>
<Month>09</Month>
<Day>18</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>France</Country>
<MedlineTA>Ann Endocrinol (Paris)</MedlineTA>
<NlmUniqueID>0116744</NlmUniqueID>
<ISSNLinking>0003-4266</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C508600">IL6 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011991">Receptors, Virus</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D013963">Thyroid Hormones</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>4QWG6N8QKH</RegistryNumber>
<NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>9002-71-5</RegistryNumber>
<NameOfSubstance UI="D013972">Thyrotropin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.15.1</RegistryNumber>
<NameOfSubstance UI="D007703">Peptidyl-Dipeptidase A</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.17.23</RegistryNumber>
<NameOfSubstance UI="C000705307">ACE2 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.17.23</RegistryNumber>
<NameOfSubstance UI="D000085962">Angiotensin-Converting Enzyme 2</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList>
<SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName UI="D000085962" MajorTopicYN="N">Angiotensin-Converting Enzyme 2</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000073640" MajorTopicYN="Y">Betacoronavirus</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000080424" MajorTopicYN="N">Cytokine Release Syndrome</DescriptorName>
<QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
<QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D004198" MajorTopicYN="N">Disease Susceptibility</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D049970" MajorTopicYN="N">Graves Ophthalmopathy</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D007037" MajorTopicYN="N">Hypothyroidism</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
<QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName>
<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D058873" MajorTopicYN="Y">Pandemics</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D007703" MajorTopicYN="N">Peptidyl-Dipeptidase A</DescriptorName>
<QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D010902" MajorTopicYN="N">Pituitary Gland</DescriptorName>
<QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D011991" MajorTopicYN="N">Receptors, Virus</DescriptorName>
<QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D013959" MajorTopicYN="N">Thyroid Diseases</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
<QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D013961" MajorTopicYN="N">Thyroid Gland</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
<QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D013963" MajorTopicYN="N">Thyroid Hormones</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D013971" MajorTopicYN="N">Thyrotoxicosis</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
<QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D013972" MajorTopicYN="N">Thyrotropin</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">COVID-19</Keyword>
<Keyword MajorTopicYN="N">Free T3</Keyword>
<Keyword MajorTopicYN="N">Free T4</Keyword>
<Keyword MajorTopicYN="N">Hypothyroidism</Keyword>
<Keyword MajorTopicYN="N">Hypothyroïdie</Keyword>
<Keyword MajorTopicYN="N">Orbitopathie</Keyword>
<Keyword MajorTopicYN="N">Orbitopathy</Keyword>
<Keyword MajorTopicYN="N">SARS-CoV-2</Keyword>
<Keyword MajorTopicYN="N">T3l</Keyword>
<Keyword MajorTopicYN="N">T4l</Keyword>
<Keyword MajorTopicYN="N">TSH</Keyword>
<Keyword MajorTopicYN="N">Thyrotoxicose</Keyword>
<Keyword MajorTopicYN="N">Thyrotoxicosis</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="pubmed">
<Year>2020</Year>
<Month>9</Month>
<Day>21</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2020</Year>
<Month>10</Month>
<Day>30</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2020</Year>
<Month>9</Month>
<Day>20</Day>
<Hour>20</Hour>
<Minute>26</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">32950466</ArticleId>
<ArticleId IdType="pii">S0003-4266(20)31214-2</ArticleId>
<ArticleId IdType="doi">10.1016/j.ando.2020.09.001</ArticleId>
<ArticleId IdType="pmc">PMC7498405</ArticleId>
</ArticleIdList>
<ReferenceList>
<Reference>
<Citation>J Endocrinol Invest. 2020 Aug;43(8):1171-1172</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32488726</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Eur J Pharmacol. 2020 Nov 5;886:173451</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32768505</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2020 Apr 30;382(18):1708-1720</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32109013</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Endocrinol Invest. 2020 Aug;43(8):1149-1151</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32441005</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Endocrinol (Oxf). 2005 Aug;63(2):197-202</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16060914</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet Diabetes Endocrinol. 2020 Sep;8(9):739-741</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32738929</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Virol J. 2009 Jan 12;6:5</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19138419</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Endocrinology. 2020 Sep 1;161(9):</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32652001</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Endocrinol Invest. 2020 Aug;43(8):1173-1174</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32504458</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Allergy. 2020 Jul;75(7):1730-1741</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32077115</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Zhonghua Bing Li Xue Za Zhi. 2020 May 8;49(5):411-417</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32172546</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Thyroid. 2020 Jul 10;:</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32600165</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Hormones (Athens). 2020 Jul 16;:</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32676935</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet Diabetes Endocrinol. 2015 Oct;3(10):816-25</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">26071885</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Diabetes Metab Syndr. 2020 Sep - Oct;14(5):767-771</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32521463</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Biochem Cell Biol. 2010 Aug;88(4):723-30</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20651845</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Postgrad Med J. 2020 Jul;96(1137):412-416</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32527756</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Endocrinol Metab. 2020 Oct 1;105(10):</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32780854</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Eur J Endocrinol. 2020 Jul;183(1):G33-G39</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32438340</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Endocrinol Invest. 2020 Aug;43(8):1169-1170</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32488724</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Thyroid. 1998 Jan;8(1):37-41</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9492151</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>BMJ. 2020 Mar 26;368:m1091</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32217556</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Endocrine. 2020 Jun;68(3):471-474</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32507963</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Microbiol Immunol Infect. 2020 Jun;53(3):368-370</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32205092</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Horm Metab Res. 2020 Jul;52(7):471-484</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32512611</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Endocrinol Metab. 2020 Aug 1;105(8):</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32525973</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Endocrinol Invest. 2020 Jul;43(7):1027-1031</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32361826</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Endocrinol Metab. 2020 Jun 1;105(6):</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32249902</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Infect Dis Poverty. 2020 Apr 28;9(1):45</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32345362</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Hum Pathol. 2007 Jan;38(1):95-102</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16996569</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Eur J Endocrinol. 2020 Oct;183(4):381-387</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32698147</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2020 May 21;382(21):2012-2022</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32227758</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Endocrinol Metab. 2020 Jul 1;105(7):</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32436948</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Asian Pac J Allergy Immunol. 2020 Mar;38(1):1-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32105090</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>BMJ. 1997 May 31;314(7094):1593</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9186170</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations>
<list>
<country>
<li>France</li>
</country>
<region>
<li>Midi-Pyrénées</li>
<li>Occitanie (région administrative)</li>
</region>
<settlement>
<li>Toulouse</li>
</settlement>
</list>
<tree>
<country name="France">
<region name="Occitanie (région administrative)">
<name sortKey="Caron, Philippe" sort="Caron, Philippe" uniqKey="Caron P" first="Philippe" last="Caron">Philippe Caron</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A75 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000A75 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidChloroV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:32950466
   |texte=   Thyroid disorders and SARS-CoV-2 infection: From pathophysiological mechanism to patient management.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:32950466" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidChloroV1 

Wicri

This area was generated with Dilib version V0.6.38.
Data generation: Sat May 22 17:02:32 2021. Site generation: Sat May 22 17:06:52 2021